Organon Pharma Mexico, S.A. de C.V.
🚨 Critical Risk
FEI: 3022529610 • Ciudad De Mexico, Ciudad de Mexico • MEXICO
FEI Number
3022529610
Location
Ciudad De Mexico, Ciudad de Mexico
Country
MEXICOAddress
Avenida 16 De Septiembre No. 301, Barrio Xaltocan, Xochimilco, Ciudad De Mexico, Ciudad de Mexico, Mexico
Critical Risk
FDA Import Risk Assessment
This firm has an extensive history of FDA import refusals with severe violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
NO ENGLISH
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(f) of the FD&C Act in that any word, statement, or other information required by or under the authority of the FD&C Act to appear on the label or labeling is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary terms of purchase and use (for example, label contains information in two or more languages but fails to repeat all required information in both languages in accordance with 21 CFR 101.15(c)(2), or label fails to include all required information in English in accordance with 21 CFR 101.15(c)(1), except in the case of articles distributed solely in the Commonwealth of Puerto Rico or in a Territory where the predominant language is one other than English)).
DRUG GMPS
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the methods used in and controls used for the manufacture, processing, packing, or holding of drugs and other products do not appear to conform to current good manufacturing practices within the meaning of Section 501(a)(2)(B).
NEW VET DR
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the Federal Food, Drug, and Cosmetic Act in that it appears to be a new animal drug that is unsafe within the meaning of Section 512(a) of the Federal Food, Drug, and Cosmetic Act as it is not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listing, and no investigational new animal drug exemption applies.
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 9/29/2025 | 60KDY15TIBOLONE (ANABOLIC) | Division of Southeast Imports (DSEI) | |
| 9/10/2024 | 61JCA15EZETIMIBE | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 8/23/2023 | 66VCY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/17/2022 | 64LDJ03BETAMETHASONE (GLUCOCORTICOID) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/6/2022 | 64LDJ03BETAMETHASONE (GLUCOCORTICOID) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/1/2021 | 64LDO06BETAMETHASONE DIPROPIONATE (GLUCOCORTICOID) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/14/2021 | 64LDK06BETAMETHASONE DIPROPIONATE (GLUCOCORTICOID) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/21/2020 | 61PCA26METFORMIN (ANTI-DIABETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/13/2020 | 61EDB08LORATADINE (ANTI-ASTHMATIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/9/2020 | 61ECY08LORATADINE (ANTI-ASTHMATIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/23/2020 | 60NCK09OXANDROLONE (ANDROGEN) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/14/2019 | 64LCY03BETAMETHASONE (GLUCOCORTICOID) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/4/2019 | 61XDA99ANTI-HISTAMINIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/7/2018 | 64LDO03BETAMETHASONE (GLUCOCORTICOID) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/5/2018 | 60LCL99ANALGESIC, N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/4/2018 | 64LCJ03BETAMETHASONE (GLUCOCORTICOID) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/30/2017 | 62GCB99ANTI-INFLAMMATORY N.E.C. | 72NEW VET DR | Division of Southeast Imports (DSEI) |
| 5/12/2017 | 64LDE06BETAMETHASONE DIPROPIONATE (GLUCOCORTICOID) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/8/2017 | 61XCA99ANTI-HISTAMINIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/4/2017 | 64LCK06BETAMETHASONE DIPROPIONATE (GLUCOCORTICOID) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 10/7/2016 | 64LCA56PREDNISONE (GLUCOCORTICOID) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 8/16/2016 | 60LBC01ACETAMINOPHEN (ANALGESIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 8/15/2016 | 66VCB99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Florida District Office (FLA-DO) |
| 6/7/2016 | 60KCA15TIBOLONE (ANABOLIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/15/2016 | 64LDY03BETAMETHASONE (GLUCOCORTICOID) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 2/21/2013 | 61EDK08LORATADINE (ANTI-ASTHMATIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 6/19/2012 | 61XCB99ANTI-HISTAMINIC N.E.C. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 6/15/2012 | 61JAC15EZETIMIBE | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 4/26/2012 | 62GDJ99ANTI-INFLAMMATORY N.E.C. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 1/4/2012 | 61W04CLOTRIMAZOLE (ANTI-FUNGAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 12/7/2011 | 66VCE99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 6/24/2008 | 62LCY50METRONIDAZOLE HYDROCHLORIDE (ANTI-PROTOZOAL, A-LEISHMANIAL, ANTI-MALARIAL) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 2/11/2008 | 60LDA01ACETAMINOPHEN (ANALGESIC) | 75UNAPPROVED | Cincinnati District Office (CIN-DO) |
| 2/6/2008 | 64GDA29LEVONORGESTREL (ESTROGEN) | 75UNAPPROVED | Cincinnati District Office (CIN-DO) |
| 2/6/2008 | 60CAL48OXYMETAZOLINE HCL (ADRENERGIC) | 75UNAPPROVED | Cincinnati District Office (CIN-DO) |
| 1/15/2008 | 61XDB99ANTI-HISTAMINIC N.E.C. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 8/27/2007 | 64LCK03BETAMETHASONE (GLUCOCORTICOID) | Cincinnati District Office (CIN-DO) | |
| 7/16/2007 | 61XDA08CHLORPHENIRAMINE MALEATE (ANTI-HISTAMINIC) | 75UNAPPROVED | Cincinnati District Office (CIN-DO) |
| 7/3/2007 | 60LDA01ACETAMINOPHEN (ANALGESIC) | 75UNAPPROVED | Cincinnati District Office (CIN-DO) |
| 4/12/2007 | 64LCA56PREDNISONE (GLUCOCORTICOID) | 75UNAPPROVED | Cincinnati District Office (CIN-DO) |
| 10/24/2005 | 66VCP99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 7/25/2005 | 61ECP08LORATADINE (ANTI-ASTHMATIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 6/28/2005 | 64LDO06BETAMETHASONE DIPROPIONATE (GLUCOCORTICOID) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 3/4/2005 | 64LDO06BETAMETHASONE DIPROPIONATE (GLUCOCORTICOID) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 12/8/2004 | 56DCJ21GENTAMICIN SULFATE (AMINOGLYCOSIDES) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 1/20/2004 | 62GCP99ANTI-INFLAMMATORY N.E.C. | New York District Office (NYK-DO) | |
| 10/3/2003 | 63JBY13EDETATE DISODIUM (CHELATING AGENT) | 118NOT LISTED | Southwest Import District Office (SWI-DO) |
| 3/11/2003 | 64LCK03BETAMETHASONE (GLUCOCORTICOID) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 10/22/2002 | 64LDJ03BETAMETHASONE (GLUCOCORTICOID) | 75UNAPPROVED | Chicago District Office (CHI-DO) |
| 10/22/2002 | 64LDJ03BETAMETHASONE (GLUCOCORTICOID) | 75UNAPPROVED | Chicago District Office (CHI-DO) |
| 4/9/2002 | 64ABR20TRICLOSAN (DISINFECTANT) | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 4/9/2002 | 64ABR20TRICLOSAN (DISINFECTANT) | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 4/9/2002 | 64ABR20TRICLOSAN (DISINFECTANT) | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 11/27/2001 | 64ADR20TRICLOSAN (DISINFECTANT) | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 11/27/2001 | 64ADR20TRICLOSAN (DISINFECTANT) | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 11/27/2001 | 64ADR20TRICLOSAN (DISINFECTANT) | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 11/20/2001 | 53DH03POWDERS (DUSTING AND TALCUM, EXCLUDING AFTERSHAVE TALC) (FRAGRANCE PREPARATIONS) | Southwest Import District Office (SWI-DO) | |
| 11/20/2001 | 53DH03POWDERS (DUSTING AND TALCUM, EXCLUDING AFTERSHAVE TALC) (FRAGRANCE PREPARATIONS) | Southwest Import District Office (SWI-DO) |
Frequently Asked Questions
What is Organon Pharma Mexico, S.A. de C.V.'s FDA import refusal history?
Organon Pharma Mexico, S.A. de C.V. (FEI: 3022529610) has 58 FDA import refusal record(s) in our database, spanning from 11/20/2001 to 9/29/2025.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Organon Pharma Mexico, S.A. de C.V.'s FEI number is 3022529610.
What types of violations has Organon Pharma Mexico, S.A. de C.V. received?
Organon Pharma Mexico, S.A. de C.V. has been cited for 5 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Organon Pharma Mexico, S.A. de C.V. come from?
All FDA import refusal data for Organon Pharma Mexico, S.A. de C.V. is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.